An Expanded access study of LIVMARLI for the treatment of Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC)
Latest Information Update: 07 Aug 2023
At a glance
- Drugs Maralixibat (Primary)
- Indications Alagille syndrome; Intrahepatic cholestasis
- Focus Expanded access; Therapeutic Use
Most Recent Events
- 07 Aug 2023 New trial record
- 25 Jul 2023 According to a Mirum Pharmaceuticals media release, the company has this expanded access program open across multiple countries for eligible patients with ALGS and PFIC.